Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 21892908)

  • 1. Increased plasma concentrations of tumour markers in the absence of neoplasia.
    Trapé J; Filella X; Alsina-Donadeu M; Juan-Pereira L; Bosch-Ferrer Á; Rigo-Bonnin R;
    Clin Chem Lab Med; 2011 Oct; 49(10):1605-20. PubMed ID: 21892908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors influencing blood tumor marker concentrations in the absence of neoplasia.
    Trapé J; Fernández-Galán E; Auge JM; Carbonell-Prat M; Filella X; Miró-Cañís S; González-Fernández C;
    Tumour Biol; 2024; 46(s1):S35-S63. PubMed ID: 38517826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytokeratin 19 fragment CYFRA 21-1 compared with carcinoembryonic antigen, squamous cell carcinoma antigen and neuron-specific enolase in lung cancer. Results of an international multicentre study.
    Ebert W; Dienemann H; Fateh-Moghadam A; Scheulen M; Konietzko N; Schleich T; Bombardieri E
    Eur J Clin Chem Clin Biochem; 1994 Mar; 32(3):189-99. PubMed ID: 7518259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
    Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
    Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does the assessment of serum markers in patients with lung cancer aid in the clinical decision making process?
    Ebert W; Muley T; Drings P
    Anticancer Res; 1996; 16(4B):2161-8. PubMed ID: 8694537
    [TBL] [Abstract][Full Text] [Related]  

    Plavetić ND; Gnjidić M; Kulić A; Ivić M; Kukec I; Vidović M
    Lijec Vjesn; 2016; 138(3-4):85-92. PubMed ID: 30146854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review of Commonly Used Serum Tumor Markers and Their Relevance for Image Interpretation.
    Reiter MJ; Costello JE; Schwope RB; Lisanti CJ; Osswald MB
    J Comput Assist Tomogr; 2015; 39(6):825-34. PubMed ID: 26248153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer.
    Ando S; Kimura H; Iwai N; Shima M; Ando M; Kuriyama T
    Anticancer Res; 2001; 21(4B):3085-92. PubMed ID: 11712815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Value of tumour and inflammatory markers in lung cancer.
    Oremek GM; Sauer-Eppel H; Bruzdziak TH
    Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advanced ovarian cancer. Tumour markers.
    Rustin GJ; van der Burg ME; Berek JS
    Ann Oncol; 1993; 4 Suppl 4():71-7. PubMed ID: 8312203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of tumour markers, cytogenetics.
    Lamerz R
    Ann Oncol; 1999; 10 Suppl 4():145-9. PubMed ID: 10436809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of tumor markers in serum. Pitfalls and good practice.
    Basuyau JP; Leroy M; Brunelle P
    Clin Chem Lab Med; 2001 Dec; 39(12):1227-33. PubMed ID: 11798082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of a Combined Panel of Six Serum Tumor Markers for Lung Cancer.
    Molina R; Marrades RM; Augé JM; Escudero JM; Viñolas N; Reguart N; Ramirez J; Filella X; Molins L; Agustí A
    Am J Respir Crit Care Med; 2016 Feb; 193(4):427-37. PubMed ID: 26465739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum tumour markers in patients with chronic kidney disease.
    Xiaofang Y; Yue Z; Xialian X; Zhibin Y
    Scand J Clin Lab Invest; 2007; 67(6):661-7. PubMed ID: 17852811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Significance of Serum Tumor Markers in Patients with Advanced-stage NSCLC Treated with Pemetrexed-based Chemotherapy.
    Fiala O; Pesek M; Finek J; Svaton M; Sorejs O; Bortlicek Z; Kucera R; Topolcan O
    Anticancer Res; 2016 Jan; 36(1):461-6. PubMed ID: 26722082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyfra 21-1 in monitoring cervical cancer: a comparison with tissue polypeptide antigen and squamous cell carcinoma antigen.
    Bonfrer JM; Gaarenstroom KN; Korse CM; Van Bunningen BN; Kenemans P
    Anticancer Res; 1997; 17(3C):2329-34. PubMed ID: 9245246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical application of tumour markers: a review.
    Amayo AA; Kuria JG
    East Afr Med J; 2009 Dec; 86(12 Suppl):S76-83. PubMed ID: 21591514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases.
    Schneider J; Philipp M; Velcovsky HG; Morr H; Katz N
    Anticancer Res; 2003; 23(2A):885-93. PubMed ID: 12820318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of novel serum markers in clinical follow-up of Sertoli-Leydig cell tumours.
    Lenhard M; Kuemper C; Ditsch N; Diebold J; Stieber P; Friese K; Burges A
    Clin Chem Lab Med; 2007; 45(5):657-61. PubMed ID: 17484630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prognostic value of both neuron-specific enolase (NSE) and Cyfra21-1 in small cell lung cancer.
    Ando S; Suzuki M; Yamamoto N; Iida T; Kimura H
    Anticancer Res; 2004; 24(3b):1941-6. PubMed ID: 15274381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.